Drugs / Peptide-stimulated T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02580539 | Nov 2015 → May 2025 | Epstein-Barr virus infection, lymphoma, post-transplant lymphoproliferative disease | Dr. Jean-Sebastien Delisle, MD, PhD | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peptide-stimulated T cells | “Peptide-stimulated T cells 2 x 10\^7/m\^2” NCT02580539 ↗ |
| Action | Deplete | “to recognize the virus-infected cells and to eliminate them” NCT02580539 ↗ |
| Modality | Cell therapy | “immune cells (T lymphocytes)” NCT02580539 ↗ |
| Route | Other | “The cells are then transfused into the patient.” NCT02580539 ↗ |